Clinical efficacy of milbemycin oxime in the treatment of nasal mite infection in dogs

Abstract

A multicentric clinical trial was done to evaluate the clinical efficacy of milbemycin oxime in the treatment of nasal mite (Pneumonyssoides caninum) infection in dogs. Milbemycin oxime was given to 70 dogs of different breeds, genders, and ages, with clinical signs associated with nasal mite infection. Twenty-five dogs had a verified infection, and 45 dogs had signs suggestive of nasal mite infection. Milbemycin oxime was given at the dosage of 0.5 to 1.0 mg/kg body weight orally once a week for three consecutive weeks. One month after initiation of treatment, 68 of the dogs had no more clinical signs associated with nasal mite infection.

Pneumonyssoides species infestation in two Pekingese dogs in the UK

“…Proven treatment options for Pneumonyssoides include milbemycin oxime (Bredal and Vollset 1998, Gunnarsson and others 1999) and ivermectin (Mundell and Ihkre 1990, Gabriel and others 2004). More recently, it has been suggested that selamectin may be an effective treatment option (Gunnarsson and others 2004).…”

Clinicopathologic findings, sensitivity to house dust mites and efficacy of milbemycin oxime treatment of dogs withCheyletiellasp. infestation

“…Milbemycin oxime is a macrocyclic lactone that has been used in the treatment and control of many species of canine ectoparasites and endoparasites 24–29 . It has been reported previously as an effective acaracide in dogs infested with S. scabeii.…”